Neurocrine Biosciences Inc. (NBIX) Stock
NSQ · NBIX
146.23
Fundamentals
Market cap
$14.86B
Price / Earnings ratio
21.9x
Price / Sales ratio
4.6x
Price / Book ratio
4.2x
Return on assets
0.1%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees2,500
CEOMr. Kyle W. Gano Ph.D.
IPO DateMay 23, 1996
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kyle W. Gano Ph.D. | President, CEO & Director | 1973 |
| Mr. Matthew C. Abernethy CPA | Chief Financial Officer | 1980 |
| Dr. Jude Onyia Ph.D. | Chief Scientific Officer | 1964 |
| Mr. Eric S. Benevich | Chief Commercial Officer | 1965 |
| Dr. Eiry Wyn Roberts M.D. | Strategic Advisor | 1964 |
| Dr. Sanjay Keswani B.Sc., M.D., MBBS | Chief Medical Officer | 1971 |
| Dr. Wylie W. Vale Ph.D. | Co-Founder | 1942 |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder of Neurocrine | 1948 |
| Mr. Aaron Vosburgh | Senior Vice President of Finance & Accounting | — |
| Mr. Lewis Choi | Chief Information Officer | — |
Fundamentals
Valuation
Market cap$14.86B
Price-to-sales ratio4.57
Price-to-book value4.18
Price-earnings ratio21.90
Return on Equity22.00%
Return on Sales0.30%
Return on Assets0.15%
PEG ratio0.30
Earnings Per Share
Earnings Per Share$7.05
Income Statement
Average volume1,024,080
EBITDA$989.60M
1 year high (52w)$186.12
1 year low (52w)$122.14
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



